BH3-only protein targeting by HHV-8

HHV-8 仅靶向 BH3 蛋白

基本信息

  • 批准号:
    8601429
  • 负责人:
  • 金额:
    $ 40.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-01-01 至 2017-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Human herpesvirus 8 (HHV-8) is associated with endothelial Kaposi's sarcoma (KS) and B cell malignancies primary effusion lymphoma and multicentric Castleman's disease, all of which occur predominantly in the context of HIV coinfection. Both latent and lytic gene products are believed to contribute to these pathologies, and productive replication and increased viral loads are associated with KS. Understanding the processes required for successful lytic replication will provide opportunities for targeting essential viral functions to block virus replication and thereby treat or prevent HHV-8 associated disease. Key to replication by HHV-8 and other viruses are viral mechanisms that limit stress-induced apoptotic signaling that serves as an innate defense mechanism against virus infection. HHV-8 encodes several proteins that inhibit such pro-apoptotic pathways. These proteins include viral interferon regulatory factor-1 (vIRF-1), viral G protein coupled receptor (vGPCR), and viral chemokines vCCL-1 and vCCL-2, all of which have been demonstrated to both inhibit apoptosis and be required for efficient virus replication. This laboratory has identified inhibitor interactions of vIRF-1 with replication-induced pro-apoptotic BH3-only proteins (BOPs) Bim and Bid and revealed the critical importance of controlling these proteins for efficient virus replicaton to occur. Suppression of Bim or Bid expression via transduced shRNAs leads to very significant increases in virus replication, and disruption of vIRF-1:BOP interactions inhibits virus production and promotes apoptosis in lytically infected cells. In addition to Bim and Bid, vIRF-1 targets other BOPs (Bik, Bmf, Hrk, Noxa), via their functional BH3 domains, indicating the biological importance of these BOPs also and the need to inhibit their activities during lytic replication. Furthermore, the viral chemokine receptor (vGPCR) and CCR8 agonists vCCL-1 and vCCL-2 activate signaling pathways that lead to suppression of Bim expression. Thus, chemokine receptor signaling is likely to enhance HHV-8 productive replication in part via BOP regulation. This application proposes to: (1) elucidate the mechanisms of vGPCR and vCCL suppression of Bim, an identified major inhibitor of HHV-8 replication; (2) identify peptide and pharmacological inhibitors of vIRF-1:BOP interactions to specifically inhibit this mechanism of BOP regulation; (3) determine the antiviral activities of lytic cycle-induced BOPs and the individual and combined contributions, via BOP control, of vCCLs, vGPCR, and vIRF-1 to HHV- 8 productive replication. The project comprises a focused analysis of BOP function and targeting by vCCLs, vGPCR and vIRF-1 during HHV-8 lytic replication and assessment of inhibitory reagents and methods that could potentially be developed for antiviral purposes.
描述(由申请人提供):人类疱疹病毒 8 (HHV-8) 与内皮卡波西肉瘤 (KS) 和 B 细胞恶性肿瘤、原发性渗出性淋巴瘤和多中心 Castleman 病相关,所有这些主要发生在 HIV 共感染的情况下。据信潜伏基因产物和裂解基因产物都会导致这些病理学,并且高效复制和病毒载量增加与 KS 相关。了解成功裂解复制所需的过程将为靶向基本病毒功能以阻止病毒复制提供机会,从而治疗或预防 HHV-8 相关疾病。 HHV-8 和其他病毒复制的关键是限制应激诱导的细胞凋亡信号传导的病毒机制,该信号传导是针对病毒感染的先天防御机制。 HHV-8 编码多种抑制此类促凋亡途径的蛋白质。这些蛋白质包括病毒干扰素调节因子-1 (vIRF-1)、病毒 G 蛋白偶联受体 (vGPCR) 以及病毒趋化因子 vCCL-1 和 vCCL-2,所有这些蛋白质均已被证明能够抑制细胞凋亡,并且是有效病毒复制所必需的。该实验室已经确定了 vIRF-1 与复制诱导的促凋亡 BH3 蛋白 (BOP) Bim 和 Bid 的抑制剂相互作用,并揭示了控制这些蛋白对于有效病毒复制发生的至关重要性。通过转导的 shRNA 抑制 Bim 或 Bid 表达会导致病毒复制显着增加,并且破坏 vIRF-1:BOP 相互作用会抑制病毒产生 并促进裂解感染细胞的凋亡。除了 Bim 和 Bid 之外,vIRF-1 通过其功能性 BH3 结构域还靶向其他 BOP(Bik、Bmf、Hrk、Noxa),这表明这些 BOP 的生物学重要性以及在裂解复制过程中抑制其活性的需要。此外,病毒趋化因子受体 (vGPCR) 和 CCR8 激动剂 vCCL-1 和 vCCL-2 激活信号通路,从而抑制 Bim 表达。因此,趋化因子受体信号传导可能部分通过 BOP 调节增强 HHV-8 的高效复制。本申请旨在:(1) 阐明 vGPCR 和 vCCL 对 Bim 的抑制机制,Bim 是一种已确定的 HHV-8 复制的主要抑制剂; (2) 鉴定 vIRF-1:BOP 相互作用的肽和药理学抑制剂,以特异性抑制 BOP 调节的这种机制; (3) 确定裂解循环诱导的 BOP 的抗病毒活性,以及​​通过 BOP 控制,vCCL、vGPCR 和 vIRF-1 对 HHV-8 生产性复制的单独和组合贡献。该项目包括重点分析 HHV-8 裂解复制过程中 BOP 功能和 vCCL、vGPCR 和 vIRF-1 的靶向,以及评估可能用于抗病毒目的的抑制试剂和方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

John Nicholas其他文献

John Nicholas的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('John Nicholas', 18)}}的其他基金

USP7 targeting by HHV-8 vIRFs
HHV-8 vIRF 靶向 USP7
  • 批准号:
    9883702
  • 财政年份:
    2019
  • 资助金额:
    $ 40.5万
  • 项目类别:
USP7 targeting by HHV-8 vIRFs
HHV-8 vIRF 靶向 USP7
  • 批准号:
    10361554
  • 财政年份:
    2019
  • 资助金额:
    $ 40.5万
  • 项目类别:
USP7 targeting by HHV-8 vIRFs
HHV-8 vIRF 靶向 USP7
  • 批准号:
    10581544
  • 财政年份:
    2019
  • 资助金额:
    $ 40.5万
  • 项目类别:
HHV-8 vIRF interactions in the context of infection
HHV-8 vIRF 在感染情况下的相互作用
  • 批准号:
    8994365
  • 财政年份:
    2015
  • 资助金额:
    $ 40.5万
  • 项目类别:
HHV-8 vIRF interactions in the context of infection
HHV-8 vIRF 在感染情况下的相互作用
  • 批准号:
    9085244
  • 财政年份:
    2015
  • 资助金额:
    $ 40.5万
  • 项目类别:
Inhibitory targeting of HHV-8 vIL-6-related interactions.
HHV-8 vIL-6 相关相互作用的抑制性靶向。
  • 批准号:
    8595304
  • 财政年份:
    2013
  • 资助金额:
    $ 40.5万
  • 项目类别:
BH3-only protein targeting by HHV-8
HHV-8 仅靶向 BH3 蛋白
  • 批准号:
    9193611
  • 财政年份:
    2013
  • 资助金额:
    $ 40.5万
  • 项目类别:
BH3-only protein targeting by HHV-8
HHV-8 仅靶向 BH3 蛋白
  • 批准号:
    8537068
  • 财政年份:
    2013
  • 资助金额:
    $ 40.5万
  • 项目类别:
Inhibitory targeting of HHV-8 vIL-6-related interactions.
HHV-8 vIL-6 相关相互作用的抑制性靶向。
  • 批准号:
    8467210
  • 财政年份:
    2013
  • 资助金额:
    $ 40.5万
  • 项目类别:
BH3-only protein targeting by HHV-8
HHV-8 仅靶向 BH3 蛋白
  • 批准号:
    8786056
  • 财政年份:
    2013
  • 资助金额:
    $ 40.5万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 40.5万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 40.5万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 40.5万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 40.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 40.5万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 40.5万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 40.5万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 40.5万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 40.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 40.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了